Solriamfetol and CBT-I in Patients With Insomnia Disorder
Part of paid clinical trials in Philadelphia, Pennsylvania.
- Sponsor
- University of Pennsylvania
- Study ID
- NCT05838430
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 25 Years - 60 Years
- Healthy Volunteers
- Not accepted
Interventions
- Solriamfetol 75 MG — DRUGSolriamfetol (trade name Sunosi), is a norepinephrine-dopamine reuptake inhibitor available in 75mg and 150mg tablets for oral administration during the day. Solriamfetol's primary indication is to treat excessive daytime sleepiness (EDS) in patients diagnosed with obstructive sleep apnea or Narcolepsy. It binds to the dopamine and the norepinephrine transporters with affinities (Ki) of 14.2 μM and 3.7 μM, respectively),does not undergo significant metabolism in humans, and has a Tmax of \~2 hours (range 1.25-3.0 hours) and a T1/2 of \~7.1 hours.
- Cognitive Behavioral Therapy for Insomnia (CBT-I) — BEHAVIORALTreatment will be conducted via a HIPAA compliant video link (Zoom). Sessions 1-8 will follow our published protocol (published in 2005 by Springer). Each session will be conducted individually and have a singular focus per session. All sessions following the delivery of sleep restriction therapy \& stimulus control instructions (post Session 2) will include, as needed, management of non-adherence and/or time-in-bed titration.
- Monitoring — OTHERNo CBT-I will be administered, however, the tracking system used for CBT-I will be used for all subject conditions. This includes a sleep disorder symptoms screener, the administration of several questionnaires on a weekly basis, and the administration of daily sleep diaries online or via iPhone. Note: it is a common effect that regular monitoring of this type produces perceived clinical benefit.
- Placebo — OTHERPlacebo, identical in appearance to the active drug.
Study Details
Medication is FDA approved. The objective of this project is to test the efficacy of solriamfetol for treating insomnia (alone and in combination with Cognitive Behavioral Therapy for Insomnia \[CBT-I\]). Ultimately, this study will test whether wake extension (regardless of how it is achieved) will consolidate sleep and improve sleep continuity.
Key Dates
- Start date
- Jul 31, 2023
- Status verified
- May 2026
- Primary completion
- Jan 31, 2026
- Completion
- Apr 30, 2026
Study Design
- Enrollment
- 115 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- FACTORIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Solriamfetol+ CBT-I
- Experimental: Solriamfetol Only
- Active Comparator: Placebo + CBT-I
- Placebo Comparator: Placebo Only
Primary Outcome Measure
Sleep Continuity [ Time Frame: End of Treatment (12 Weeks) ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Pennsylvania, Behavioral Sleep Medicine Program | Philadelphia | Pennsylvania | 19104 | - |
Find similar trials in Philadelphia, PA
By condition
By specialty
Related Studies
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Recruiting · Duke University · Phoenix, Arizona
- Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in InsomniaEARLY_PHASE1 · Recruiting · Milton S. Hershey Medical Center · Denver, Colorado
- A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)PHASE3 · Recruiting · Merck Sharp & Dohme LLC · New Haven, Connecticut
- Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia SymptomsPHASE4 · Recruiting · Brigham and Women's Hospital · Boston, Massachusetts